Tumor infiltrating lymphocyte (TIL) therapy for cancer treatment, illustration. During TIL therapy, T-cells (blue) that recognize tumor cells (red) are obtained from a patient.

Evaxion Biotech, which specializes in AI platforms for antigen discovery, has reported one-year interim data from a Phase II trial (NCT05309421) underway for its peptide-based personalized cancer ...

We showed that in animal models, the MUC1* CAR-1XX increased CAR T-cell persistence and suppressed tumor recurrence by enabling the killing of low antigen-expressing cancer cells.

New research reveals how common dietary proteins like bovine serum albumin (BSA) or ovalbumin (OVA) may stimulate the body’s immune response and reduce small intestine cancer. In a recent study ...

These newly recognized cancer-specific proteins, or antigens, could speed the development of potent immunotherapies that recognize and attack hard-to-treat tumors.

Antigen preparation: Scientists can produce cancer vaccines against tumors by using the patient’s tumor as a source of antigen or by synthesizing peptides from tumor antigens. 2. Antigen delivery: ...

Mayo Clinic researchers have discovered a new immunotherapy target, a cryptic antigen, that may be key in helping the immune ...

Study shows that dietary antigens can suppress small intestine carcinogenesis by activating T-cells through Peyer's patches. Adding bovine serum albumin (BSA) or ovalbumin (OVA) to antigen-free ...

Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% of cases of pancreatic cancer, and prognosis for PDAC remains poor despite treatment advances. One reason is that PDAC downregulates ...